Aurobindo Pharma Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.

Profit growth above 25%EBITDA margin expansionExceptional itemRelated-party transactionsResults View source PDF Explain this filing

AUROPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-5.3%Reaction day

₹1549.50

prior close

₹1520.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.1%-5.4% vs market

Pharmaceuticals peers, median of 164sector-0.1%-5.2% vs sector

On the reaction day the stock moved 5.4 pts less than Nifty Midcap 150 and 5.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-1.6

10m

-2.0

15m

-2.6

30m

-2.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-5.3+0.1-5.4-0.1-5.2

Next day

-6.1+1.0-7.1+0.9-7.0

-5.9+1.4-7.3+0.9-6.8

-7.6+1.8-9.4+0.7-8.3

-8.2+0.4-8.6+0.9-9.1

-7.3-1.0-6.3+0.0-7.3

-7.4-1.2-6.2-0.0-7.4

15d

-9.4+0.5-9.9+1.2-10.6

-3.5+2.6-6.1+3.0-6.5

-1.1+2.0-3.1+4.7-5.9

+3.9+4.2-0.3+7.9-4.1

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Aurobindo Pharma reported strong standalone performance for FY26 with profit after tax of Rs 24,148 million, up 38.2% from Rs 17,468 million in FY25, driven by higher other income and controlled costs. Consolidated revenue grew 6.4% to Rs 333,847 million, but consolidated PAT was flat at Rs 35,030 million vs Rs 34,836 million. The company completed a Rs 8,000 million share buyback in May 2026. Auditors issued unmodified opinions on both standalone and consolidated results. Exceptional items of Rs 173.8 million (standalone) and Rs 653.3 million (consolidated) relate to increased employee liabilities from new labour codes.

Likely market impact

Strong standalone earnings growth with 38% PAT increase is positive for the stock. However, flat consolidated PAT despite revenue growth suggests margin pressures at the group level. The clean audit opinion and completed buyback provide investor comfort.